Archive: 04/04/2016

No improvements with losmapimod after heart attack

Patients taking losmapimod, an anti-inflammatory drug currently being developed, for 12 weeks following a heart attack did not show improvements in the trial's primary endpoint, the rate of cardiovascular death, subsequent ...

A chink in the armor of breast cancer cells

Working with human breast cancer cells, a team of scientists from Ann & Robert H. Lurie Children's Hospital of Chicago have successfully turned off a misbehaving protein that fuels the growth of a particularly aggressive, ...

Engaging patients and the public with health care evidence

At a time when public health agencies and health care providers are striving to make health care and health policy decisions on the basis of evidence, it is important for patients and the public to engage with the production, ...

page 2 from 13